Format:
10
ISSN:
1471-2407
Content:
About 50% of non-small cell lung cancer (NSCLC) patients have metastatic disease at initial diagnosis, which limits their treatment options and, consequently, the 5-year survival rate (15%). Immune checkpoint inhibitors (ICI), either alone or in combination with chemotherapy, have become standard of care (SOC) for most good performance status patients. However, most patients will not obtain long-term benefit and new treatment strategies are therefore needed. We previously demonstrated clinical safety of the tumour-selective immunocytokine L19-IL2, consisting of the anti-ED-B scFv L19 antibody coupled to IL2, combined with stereotactic ablative radiotherapy (SABR).
Note:
Gesehen am 17.09.2020
In:
BMC cancer, London : BioMed Central, 2001, 20(2020) Artikel-Nummer 557, 10 Seiten, 1471-2407
In:
volume:20
In:
year:2020
In:
extent:10
Language:
English
DOI:
10.1186/s12885-020-07055-1
URL:
Volltext
(lizenzpflichtig)